Calcitonin Gene-Related Peptide Monoclonal Antibody Treatments for Migraine

@article{Loder2019CalcitoninGP,
  title={Calcitonin Gene-Related Peptide Monoclonal Antibody Treatments for Migraine},
  author={Elizabeth W. Loder and William Renthal},
  journal={JAMA Internal Medicine},
  year={2019},
  volume={179},
  pages={421–422}
}
Background Migraine is a disabling condition determined by both genetic and environmental factors. It affects an estimated 32 million people in the United States2 and produces a lifelong predisposition to develop severe headache and associated symptoms spontaneously or in response to triggers. Occasional migraine attacks usually are treated individually with symptomatic medications such as triptans. If attacks are frequent, regularly administered preventive treatment may decrease headache… 

What's New in the Treatment of Migraine.

  • K. Digre
  • Medicine, Biology
    Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
  • 2019
TLDR
The contribution of new classes of migraine-specific therapies are summarized, including CGRP antibodies for prevention and inhibitors referred to as gepants (ubrogepant and rimegepants) for acute treatment.

New-and surprising-ways to approach migraine pain.

  • Hickner
  • Medicine
    The Journal of family practice
  • 2022
TLDR
Two recent randomized trials demonstrated that ≥ 2000 IU/d of vitamin D reduced monthly migraine days an average of 2 days, which is comparable to the effectiveness of the calcium gene-related peptide antagonists at a fraction of the cost.

Real-world effectiveness and tolerability of erenumab: A retrospective cohort study

TLDR
This large “real-world” study validates the findings of benefit of erenumab observed in clinical trials and suggests systematic differences between clinical trial participants and patients who receive the treatment in clinical practice may indicate suboptimal ascertainment of adverse events in the trials.

The prevalence and impact of migraine and severe headache in the United States: Updated age, sex, and socioeconomic‐specific estimates from government health surveys

TLDR
Data from US government health surveys is used to report the prevalence, trends, and impact of migraine by age, sex, and poverty status.

References

SHOWING 1-6 OF 6 REFERENCES

Migraine prevalence, disease burden, and the need for preventive therapy

TLDR
The epidemiologic profile of migraine has remained stable in the United States during the past 15 years and more than one in four migraineurs are candidates for preventive therapy, and a substantial proportion of those who might benefit from prevention do not receive it.

A Comparative Effectiveness Meta-Analysis of Drugs for the Prophylaxis of Migraine Headache

TLDR
Network meta-analysis found amitriptyline to be better than several other medications including candesartan, fluoxetine, propranolol, topiramate and valproate and no different than atenolol, flunarizine, clomipramine or metoprolol.

The Prevalence and Impact of Migraine and Severe Headache in the United States: Figures and Trends From Government Health Studies

TLDR
The goal was to assess the stability of prevalence estimates over time, and to identify additional information pertinent to the burden and treatment of migraine and other severe headache conditions.

New preventive treatments for migraine

TLDR
High prices put promising monoclonal antibodies out of reach for many patients, according to research published in The Lancet Oncology journal.

The prevalence and impact of migraine and severe headache in the united states: figures and trends from government health studies. Headache

  • 2018

The prevalence and impact of migraine and severe

  • headache